[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsedrefractory-peripheral-t-cell-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsedrefractory-peripheral-t-cell-lymphoma":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,64,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100453316","phase-2-clinical-study-on-anti-pd-1-plus-lenalidomide-and-azacitidine-in-relapsedrefractory-peripheral-t-cell-lymphoma-100453316",false,"NCT05182957","Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed\u002FRefractory Peripheral T-cell Lymphoma","Clinical Study on the Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Combined Lenalidomide and Azacitidine in Relapsed\u002FRefractory Peripheral T-cell Lymphoma","Inclusion Criteria:\n\n1. Pathological immunohistochemistry or flow cytometry confirmed that R\u002FR PTCL with measurable (diameter greater than 1.5cm) lesions meets any of the following conditions: 1\\> After 4 courses of standard first-line therapy or 2 courses of more than two-line therapy, the lesions were reduced by \\\u003C50%; 2\\> PTCL with disease progression after first-line or induction therapy; 3\\> After hematopoietic stem cell transplantation, new lesions appear or the size of previously affected lesions increased by more than 50%.\n2. Age ≥ 18 years.\n3. ECOG≤2分.\n4. The main organ functions need to meet the following conditions:Hemogram needs to meet HB ≥70\\*1012\u002FL，PLT≥50\\*109\u002FL，NE≥1\\*109\u002FL；LVEF≥50%;CR≤132umol\u002Fl or CCr≥60 ml\u002Fmin;ALT and AST≤2 times normal range；Lung function≤Level 1;dyspnea(CTCAE v5.0),and blood oxygen saturation without oxygen absorption\\> 91%.\n5. Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up one year period of the study.\n6. Estimated survival time ≥3 months.\n7. Voluntary signing of informed consent.\n\nExclusion Criteria:\n\n1. Accepted major surgery within 4 weeks before treatment.\n2. Prior malignancy (other than Relapsed\u002FRefractory Peripheral T-cell Lymphoma), except for cured malignant tumors with no active lesions for 3 years;Adequate treatment of inactive lesions in non-melanoma skin cancer,malignant tonsilloma or carcinoma in situ;\n3. Patients who have previously received failed allogeneic hematopoietic stem cell transplantation.\n4. Have stroke or intracranial hemorrhage within 3 months.\n5. Evidence of complications or medical conditions, including but not limited, that may interfere the conduct of the study or place the patient at serious risk:significant cardiovascular disease(class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification、myocardial infarction within 6 months of screening、uncontrolled or symptomatic arrhythmias) and\u002For significant lung disease.\n6. HIV infection and\u002For active hepatitis B or active hepatitis C.\n7. Uncontrolled systemic infection.\n8. Pregnant or breasting-feeding women.\n9. According to the researchers' judgment, any life-threatening disease, medical condition or organ system dysfunction which can endanger the patient's safety and Interfer with the absorption or metabolism of anti-PD-1 monoclonal antibody plus Lenalidomide and Azacitidine,may put the results of a study at unnecessary risk.","ALL","18 Years",{"count":19,"type":20},31,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed\u002FRefractory Peripheral T-cell Lymphoma Patients.",[26],"Relapsed\u002FRefractory Peripheral T-cell Lymphoma",[28],"Anti-PD-1 monoclonal antibody,Lenalidomide,Azacitidine","RECRUITING","2026-04-26",{"date":32,"type":33},"2026-05-01","ACTUAL",{"date":35,"type":33},"2020-01-01",{"date":37,"type":20},"2026-06-15",{"name":39,"class":40},"The First Affiliated Hospital of Soochow University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":41},"100556010","phase-2-exploratory-clinical-study-of-shr-0302-and-shr-2554-in-patients-with-relapsedrefractory-peripheral-t-cell-lymphoma-100556010","NCT06519526","Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed\u002FRefractory Peripheral T Cell Lymphoma","Inclusion Criteria:\n\n* Males or females aged 18-70 years (inclusive);\n* Histologically confirmed peripheral T-cell lymphoma;\n* Disease status defined as relapsed or refractory after \\>=1 prior systemic treatment lines;\n* Have measurable lesions;\n* ECOG performance status must be 0 or 1 and has not deteriorated in the past 2 weeks;\n* Life expectancy ≥12 weeks;\n* Adequate bone marrow reserve and organ system function reserve;\n* Participants should be able and willing to comply with the study protocol requirement;\n\nExclusion Criteria:\n\n* Received anti-tumor treatment within 28 days prior to the first dose of the study drug; received Chinese medicine treatment with anti-tumor effect within 14 days before the first dose of the study drug; received steroid hormones within 7 days prior to the first dose of study drug administration;\n* Underwent major surgery within 4 weeks prior to the first dose of study treatment；\n* Severe cardiovascular disease;\n* Cerebrovascular accident or transient ischemic attack within 6 months prior to enrollment;\n* Significant impairment of lung function;\n* Active infections;\n* Unexplained fever \\> 38.5°C during screening period or on the first day of medication;\n* Pregnant;\n* Known alcohol or drug abuse;\n* Subjects are currently receiving known moderately potent or potent CYP inducers\u002Finhibitors or P-glycoprotein (P-gp) inhibitors;\n* History of hypersensitivity to the investigational drug or its excipients;\n* In the judgment of the investigator, objective conditions make the subject unable to complete the planned study or the subject has other factors, concomitant diseases, combined treatment or abnormal laboratory examination that may lead to the forced termination of the study.","70 Years",{"count":50,"type":20},25,[23],"This is an open-label, prospective and exploratory clinical study to evaluate the efficacy and safety of JAK inhibitor SHR-0302 in combination with EZH2 inhibitor SHR-2554 in patients with R\u002FR PTCL. The study plans to enroll approximately 25 patients. 6-12 patients will receive SHR-0302 monotherapy and SHR-0302+SHR-2554 combination therapy in the safety run-in phase. According to the safety observed, the investigators discuss and decide to select a dose group to explore the efficacy and safety. 13 patients may be enrolled in the expansion phase.",[54],"Relapsed\u002FRefractory Peripheral T Cell Lymphoma","2026-03-20",{"date":57,"type":33},"2026-03-24",{"date":59,"type":33},"2024-08-12",{"date":61,"type":20},"2027-08-31",{"name":63,"class":40},"Fudan University",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100575797","phase-3-a-randomized-double-blind-multicenter-phase-iii-study-of-xnw5004-tablets-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-100575797","NCT06776952","A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","Inclusion Criteria:\n\n* Aged 18-70 years (inclusive)，gender not limited.\n* Pathologically diagnosed, relapsed or refractory peripheral T-cell lymphoma.\n* Disease status defined as relapsed or refractory after \\>=1 prior systemic treatment lines, and have not received treatment with HDAC inhibitors, subjects with NK\u002FT-cell lymphoma require treatment with a regimen containing asparaginase\u002Fprotease, subjects with CD30 positive ALCL require prior treatment with Brentuximab vedotin.\n* Subjects who have received prior radiotherapy are allowed to enroll, but radiotherapy alone is not considered a systemic therapy.\n* Having at least one measurable lesion for evaluation.\n* Agree to provide archived tumor tissue samples or fresh tumor tissue samples that meet the requirements.\n* Life expectancy of at least 12 weeks.\n* Subjects must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Have adequate organ function.\n* Females of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.Non-sterile subjects must be willing to use a highly effective contraception (e.g., IUD, pill, or condom) for the duration of the study and for 6 months after the last dose of study drug unless their partner is sterilized. For male subjects whose partner is a woman of childbearing potential, surgical sterilization or agreement to use effective contraception for the duration of the study and for 6 months after the last dose of study drug is required. In addition, males must agree not to donate sperm during the study participation and for at least 6 months after the last dose of study drug.\n* Able to provide written informed consent form prior to the commencement of any study activity\u002Fprocedure.\n\nExclusion Criteria:\n\n* Prior exposure to EZH2 inhibitor(s) or EZH1\u002F2 inhibitor(s).\n* Prior exposure to HDAC inhibitor(s).\n* Subjects with known hypersensitivity to the study drug or its active ingredients or excipients.\n* Subjects who have received anti-tumor therapy, such as chemotherapy, immunotherapy, radiotherapy, and targeted therapy, within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of the study drug, received CAR-T therapy within 12 weeks prior to the first dose of the study drug, autologous hematopoietic stem cell transplantation (Auto-HSCT) within 3 months prior to the first dose of the study drug.\n* Subjects who have received other anti-tumor investigational drug treatment within 28 days prior to the first dose of XNW5004 in this study.\n* Subjects who have undergone major surgery within 4 weeks prior to the start of study treatment or who intend to undergo major surgery during this study (except for procedures such as puncture or lymph node biopsy).\n* Subjects who have an allogeneic hematopoietic stem cell transplantation or solid organ transplantation.\n* Subjects who have received systemic treatment with corticosteroids (prednisone at a dose of \\> 10 mg per day or equivalent doses of other glucocorticoids) or other immunosuppressive drugs within 14 days prior to the use of the study drug. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal replacement therapy with prednisone at a dose of ≤ 10 mg per day or equivalent doses of other glucocorticoids are permitted.\n* Subjects taking known strong CYP3A4 inhibitors\u002Finducers and P-glycoprotein (P-gp) inhibitors within 14 days prior to the first dose.\n* Subjects who have received live virus vaccines (including live attenuated vaccines) within 28 days prior to dosing. Inactivated vaccines are permitted.\n* Subjects with a history of psychotropic drug abuse or drug abuse.\n* Subjects who have received anti-tumor therapy in the early stage and have not recovered from toxicity (toxicity has not recovered to ≤ Grade 1 according to NCI-CTCAE 5.0). Except for other toxicities (such as alopecia, etc.) that do not affect the safety evaluation of subjects in the opinion of the investigator.\n* Subjects with history of other malignancies within 3 years prior to enrollment and not meeting clinical cure criteria. Exceptions are the following: cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, intraductal carcinoma in situ of the breast, and papillary carcinoma of the thyroid that can be treated locally.\n* Subjects with mycosis fungoides, Sézary syndrome, or primary cutaneous T-cell lymphoma.\n* Subjects with previous or current central nervous system invasion.\n* Subjects with previous or current testicular or breast invasion.\n* Subjects with previous or current hemophagocytic syndrome.\n* Subjects with previous or current primary or secondary hematologic diseases that may affect bone marrow function in addition to primary malignancies, such as immune thrombocytopenia, autoimmune hemolytic anemia, aplastic anemia, etc.\n* Subjects with previous or current acute myeloid leukemia (AML).\n* Subjects with previous or current T-cell lymphoblastic lymphoma (T-LBL) or T-lymphoblastic leukemia.\n* Subjects who have any history of myeloid malignancy, including myelodysplastic syndrome (MDS), or abnormal tests results of markers related to MDS or myeloproliferative neoplasm (MPN).\n* Subjects who previously hadcentral nervous system lesions, or diseases accompanies with central nervous system lesions, including but not limited to, epilepsy, paralysis, stroke, severe brain injury, Alzheimer's disease, Parkinson's disease, cerebellar disease, cerebral organic syndrome, or psychosis, etc.\n* Subjects with clinically significant cardiovascular disease.\n* Tumor invasion of important peripheral organs and blood vessels (such as heart and pericardium, trachea, esophagus, aorta, superior vena cava, etc.) posing a risk of bleeding or the risk of esophageal tracheal fistula or esophageal pleural fistula.\n* Subjects with clinically symptomatic thoracoabdominal effusion or pericardial effusion that are poorly controlled after repeated treatment.\n* Subjects with unexplained fever and body temperature\\>38.0 ℃.\n* Subjects who have severe active systemic infection.\n* Subjects with a history of tuberculosis infection within one year prior to enrollment, or with a history of active tuberculosis infection more than one year ago without sufficient anti tuberculosis treatment.\n* A known history of HIV infection or acquired immunodeficiency syndrome (AIDS), or Anti- Treponema Pallidum test (anti-TP) positive.\n* Subjects who have HBV-DNA copy numbers higher than the lower normal limit of the detection value. Subjects with HCV-RNA copy number higher than the lower normal limit of the detection value.\n* Subjects who are unable to swallow or has a history of active gastrointestinal inflammation, chronic diarrhea, known diverticular disease, or has undergone gastrectomy or gastric banding that affects drug absorption. But gastroesophageal reflux that has been treated with proton pump inhibitors is allowed (if there is no possibility of drug interaction).\n* Subjects with conditions known to have bleeding tendencies, such as von Willebrand disease or hemophilia.\n* Subjects who are pregnant or breastfeeding, or expects to conceive within the projected duration of the study.\n* Subject who may not be able to complete this study for other reasons or who, in the opinion of the investigator, should not participate the study.","18 Days","70 Days",{"count":73,"type":20},120,[75],"PHASE3","This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed\u002FRefractory PTCL, with a target of enrolling 120 subjects.",[54],"2026-01-07",{"date":80,"type":33},"2026-01-09",{"date":82,"type":33},"2025-04-10",{"date":84,"type":20},"2028-04",{"name":86,"class":87},"Evopoint Biosciences Inc.","INDUSTRY",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100570081","phase-2-to-evaluate-xnw5004-tablets-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma-100570081","NCT06702605","To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma","A Phase II Clinical Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma","Inclusion Criteria:\n\n* Aged 18-70 years (inclusive)，gender not limited.\n* Pathologically diagnosed, relapsed or refractory peripheral T-cell lymphoma.\n* Disease status defined as relapsed or refractory after \\>=2 prior systemic treatment lines, including at least one new drug; subjects with CD30 positive ALCL requires prior treatment with Brentuximab vedotin.\n* Subjects who have received prior radiotherapy are allowed to enroll, but radiotherapy alone is not considered a systemic therapy.\n* Having at least one measurable lesion for evaluation.\n* Agree to provide archived tumor tissue samples or fresh tumor tissue samples that meet the requirements.\n* Life expectancy of at least 12 weeks.\n* Subjects must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Have adequate organ function as defined in the following requirements.\n* Females of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.Non-sterile subjects must be willing to use a highly effective contraception (e.g., IUD, pill, or condom) for the duration of the study and for 6 months after the last dose of study drug unless their partner is sterilized. For male subjects whose partner is a woman of childbearing potential, surgical sterilization or agreement to use effective contraception for the duration of the study and for 6 months after the last dose of study drug is required. In addition, males must agree not to donate sperm during the study participation and for at least 6 months after the last dose of study drug.\n* Able to provide written informed consent form prior to the commencement of any study activity\u002Fprocedure.\n\nExclusion Criteria:\n\n* Prior exposure to EZH2 inhibitor(s) or EZH1\u002F2 inhibitor(s);\n* Subjects with known hypersensitivity to the study drug or its active ingredients or excipients.\n* Subjects who have received anti-tumor therapy, such as chemotherapy, immunotherapy, radiotherapy, and targeted therapy, within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of the study drug, received CAR-T therapy within 12 weeks prior to the first dose of the study drug, autologous hematopoietic stem cell transplantation (Auto-HSCT) within 3 months prior to the first dose of the study drug.\n* Subjects who have received other anti-tumor investigational drug treatment within 28 days prior to the first dose of XNW5004 in this study.\n* Subjects who have undergone major surgery within 4 weeks prior to the start of study treatment or who intend to undergo major surgery during this study (except for procedures such as puncture or lymph node biopsy).\n* Subjects who have an allogeneic hematopoietic stem cell transplantation or solid organ transplantation.\n* Subjects who have received systemic treatment with corticosteroids (prednisone at a dose of \\> 10 mg per day or equivalent doses of other glucocorticoids) or other immunosuppressive drugs within 14 days prior to the use of the study drug. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal replacement therapy with prednisone at a dose of ≤ 10 mg per day or equivalent doses of other glucocorticoids are permitted.\n* Subjects taking known strong CYP3A4 inhibitors\u002Finducers and P-glycoprotein (P-gp) inhibitors within 14 days prior to the first dose.\n* Subjects who have received live virus vaccines (including live attenuated vaccines) within 28 days prior to dosing. Inactivated vaccines are permitted.\n* Subjects with a history of psychotropic drug abuse or drug abuse.\n* Subjects who have received anti-tumor therapy in the early stage and have not recovered from toxicity (toxicity has not recovered to ≤ Grade 1 according to NCI-CTCAE 5.0). Except for other toxicities (such as alopecia, etc.) that do not affect the safety evaluation of subjects in the opinion of the investigator.\n* Subjects with history of other malignancies within 3 years prior to enrollment and not meeting clinical cure criteria. Exceptions are the following: cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, intraductal carcinoma in situ of the breast, and papillary carcinoma of the thyroid that can be treated locally.\n* Subjects with mycosis fungoides, Sézary syndrome, or primary cutaneous T-cell lymphoma.\n* Subjects with previous or current central nervous system invasion.\n* Subjects with previous or current testicular or breast invasion.\n* Subjects with previous or current hemophagocytic syndrome.\n* Subjects with previous or current primary or secondary hematologic diseases that may affect bone marrow function in addition to primary malignancies, such as immune thrombocytopenia, autoimmune hemolytic anemia, aplastic anemia, etc.\n* Subjects with previous or current acute myeloid leukemia (AML).\n* Subjects with previous or current T-cell lymphoblastic lymphoma (T-LBL) or T-lymphoblastic leukemia.\n* Subjects who have any history of myeloid malignancy, including myelodysplastic syndrome (MDS), or abnormal tests results of markers related to MDS or myeloproliferative neoplasm (MPN).\n* Subjects who previously hadcentral nervous system lesions, or diseases accompanies with central nervous system lesions, including but not limited to, epilepsy, paralysis, stroke, severe brain injury, Alzheimer's disease, Parkinson's disease, cerebellar disease, cerebral organic syndrome, or psychosis, etc.\n* Subjects with clinically significant cardiovascular disease;\n* Tumor invasion of important peripheral organs and blood vessels (such as heart and pericardium, trachea, esophagus, aorta, superior vena cava, etc.) posing a risk of bleeding or the risk of esophageal tracheal fistula or esophageal pleural fistula.\n* Subjects with clinically symptomatic thoracoabdominal effusion or pericardial effusion that are poorly controlled after repeated treatment.\n* Subjects with unexplained fever and body temperature\\>38.0 ℃.\n* Subjects who have severe active systemic infection.\n* Subjects with a history of tuberculosis infection within one year prior to enrollment, or with a history of active tuberculosis infection more than one year ago without sufficient anti tuberculosis treatment.\n* A known history of HIV infection or acquired immunodeficiency syndrome (AIDS), or Anti- Treponema Pallidum test (anti-TP) positive.\n* Subjects who are HBsAg positive and have HBV-DNA copy numbers higher than the lower normal limit of the detection value, or subjects who are anti HBc positive and have HBV-DNA copy numbers higher than the lower normal limit of the detection value. Subjects with HCV antibody positive and HCV-RNA copy number higher than the lower normal limit of the detection value.\n* Subjects with difficulties to swallow the study drug or conditions that significantly affect gastrointestinal function, such as malabsorption syndrome, gastrectomy or small bowel resection, clinically symptomatic inflammatory bowel disease, or incomplete\u002Fcomplete intestinal obstruction.\n* Subjects who are unable to swallow or has a history of active gastrointestinal inflammation, chronic diarrhea, known diverticular disease, or has undergone gastrectomy or gastric banding that affects drug absorption. But gastroesophageal reflux that has been treated with proton pump inhibitors is allowed (if there is no possibility of drug interaction).\n* Subjects with conditions known to have bleeding tendencies, such as von Willebrand disease or hemophilia.\n* Subjects who are pregnant or breastfeeding, or expects to conceive within the projected duration of the study.\n* Subject who may not be able to complete this study for other reasons or who, in the opinion of the investigator, should not participate the study.",{"count":96,"type":20},50,[23],"This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R\u002FR PTCL. The study plans to enroll approximately 50 subjects.",[54],"NOT_YET_RECRUITING","2024-11-22",{"date":103,"type":33},"2024-11-25",{"date":105,"type":20},"2024-11",{"date":107,"type":20},"2027-01",{"name":86,"class":87},"Relapsed\u002FRefractory Peripheral T-Cell Lymphoma"]